Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Sponsor
Eye & ENT Hospital of Fudan University
Study ID
NCT05011227
Phase
PHASE2
Status
Unknown

Conditions

  • Recurrent Nasopharyngeal Carcinoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Camrelizumab — DRUG
    2 cycles Camrelizumab before endoscopic surgery and one year after
  • Chemotherapy — DRUG
    2 cycles Gemcitabine based chemotherapy before endoscopic surgery, with or without after surgery
  • endoscopic surgery — PROCEDURE
    standard endoscopic surgery for recurrent nasopharyngeal carcinoma

Study Details

To explore the effect of Camrelizumab and chemotherapy combining with endoscopic surgery in the treatment of recurrent nasopharyngeal carcinoma.

Key Dates

Start date
Aug 10, 2021
Status verified
Mar 2024
Primary completion
Aug 10, 2025
Completion
Aug 10, 2025

Study Design

Enrollment
100 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Camrelizumab and chemotherapy combined with endoscopic surgery
    Camrelizumab and chemotherapy combined with endoscopic surgery

Primary Outcome Measure

Overall Survival [ Time Frame: From date of first treatment until the date of death from any cause, up to 4 years. ]

Central Contacts

Related Studies